India, May 31 -- Pfizer Inc. (PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 BREAKWATER trial. This randomized cohort evaluated BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation.
Cohort 3 met its primary endpoint of objective response rate (ORR) by blinded independent central review (BICR). For the key secondary endpoint of progression-free survival (PFS), median PFS was nearly doubled with the BRAFTOVI combination regimen at 15.2 months compared to 8.3 months for the compara...